ubmslateCN-logo-ubm

CN Mobile Logo

Search form

Topics:

Lung Cancer

Using Immune Checkpoint Inhibitors in Lung Cancer

Immune checkpoint inhibitors have changed the treatment paradigm for patients with lung cancer, bringing about the most promising outcomes we have seen in a long time.

Lung Cancer

Pembrolizumab was associated with clinically meaningful improvements in health-related quality of life compared with platinum-based chemotherapy in NSCLC patients.

Patients treated with first-line ceritinib had a 45% reduction in the risk for progression of advanced ALK-positive NSCLC compared with chemotherapy.

Second-line treatment with osimertinib resulted in significantly better progression-free survival compared with chemotherapy alone in patients with EGFR-T790M positive NSCLC, according to the results of the AURA3 trial.

In this slide show we highlight some of the top news on lung cancer in 2016, including an immunotherapy approval from the FDA, and studies on depression in lung cancer patients, serious side effects to watch for when using immunotherapies, and more.

An updated prognostic tool incorporating gene alteration data could help guide clinical management of patients with non–small-cell lung cancer.

Cabozantinib alone or in combination with erlotinib improved survival outcomes among patients with advanced EGFR wild-type non–small-cell lung cancer.

Lung resection is gaining momentum among thoracic surgeons because it allows the operating surgeon the convenience of performing a dissection that in many ways is similar to open surgery, yet that has the advantages of a minimally invasive approach. Hopefully, surgical robotics, along with VATS, will make it possible for the thoracic surgery community to offer minimally invasive lung resection to nearly all early-stage lung cancer patients.

Pages

Subscribe to Lung Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.